Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Oramed Pharm ( (ORMP) ) has issued an announcement.
On May 21, 2025, Oramed Pharmaceuticals Inc. announced a one-year extension of its stock buyback program, allowing the company to repurchase up to $20,000,000 of its common stock until June 2026. This move reflects the company’s strategic financial management, potentially impacting its stock value and signaling confidence in its market position.
Spark’s Take on ORMP Stock
According to Spark, TipRanks’ AI Analyst, ORMP is a Neutral.
Oramed Pharm’s overall score is driven by a strong balance sheet but hindered by poor income and cash flow performance. Technical indicators are neutral, and the valuation is typical for the industry. The absence of earnings call data and significant corporate events leaves fundamental concerns unaddressed.
To see Spark’s full report on ORMP stock, click here.
More about Oramed Pharm
Oramed Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development of innovative oral drug delivery systems.
Average Trading Volume: 91,209
Technical Sentiment Signal: Strong Sell
Current Market Cap: $87.42M
For an in-depth examination of ORMP stock, go to TipRanks’ Stock Analysis page.